X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
DURYSTA® (bimatoprost intracameral implant) is a prescription medicine to reduce eye pressure in patients with open angle glaucoma or high eye pressure (ocular hypertension), approved by the FDA in March 2020.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Durysta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2022
Iran Expo
Not Confirmed
Contact SupplierDetails:
DURYSTA™ is a prostaglandin analog indicated for the reduction of IOP in patients with OAG or OHT. DURYSTA™ is an ophthalmic drug delivery system for a single intracameral administration of a biodegradable implant containing 10 mcg bimatoprost.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Durysta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 05, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
A New Drug Application (NDA) for Bimatoprost SR is currently under review with the U.S. Food and Drug Administration, and if approved, has the potential to be the first and only biodegradable.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2020
Iran Expo
Not Confirmed
Contact SupplierDetails:
SpyGlass platform is - bimatoprost implanted with the SpyGlass intraocular lens (IOL) which is designed to deliver three years of bimatoprost sustained delivery for glaucoma management.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: SpyGlass IOL
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
LL-BMT1 are contact lenses printed with bimatoprost which is a prostaglandin for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension by selectively mimicking the effects of naturally occurring substances, prostamides.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: LL-BMT1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2024
Details:
The agreement granting Kowa to focus on the development and commercialization of NCX470 (bimatoprost), Nicox’s nitric oxide, which is used for the lowering of intraocular pressure in patients with glaucoma or ocular hypertension.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: NCX 470
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kowa Pharmaceuticals America
Deal Size: $32.8 million Upfront Cash: $3.2 million
Deal Type: Licensing Agreement February 08, 2024
Details:
SpyGlass platform is - bimatoprost implanted with the SpyGlass intraocular lens (IOL) which is designed to deliver three years of bimatoprost sustained delivery for glaucoma management.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
The financing will be used to advance novel treatments for glaucoma and other chronic ophthalmic diseases, including Bimatoprost, a prostaglandin analogue.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Undislosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing July 10, 2023
Details:
The net proceeds from the financing will be used to support the launch of Zimed PF (bimatoprost) for the reduction of elevated intraocular pressure (IOP) in patients with open - angled glaucoma or ocular hypertension.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Zimed PF
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Mr. Doug Janzen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 05, 2023
Details:
Zimed PF (bimatoprost) a preservative-free, ophthalmic solution, is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension by selectively mimicking the effects of naturally occurring substances, prostamides.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Zimed PF
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
Under the agreement, Sandoz gained access to both Vistitan and Tacrolimus IR. Vistitan (bimatoprost) is a prostaglandin for IOP lowering in patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Vistitan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 29, 2022
Details:
The cash runway is based on the development of NCX 470. NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in Phase 3 clinical development for the lowering of intraocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: NCX 470
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $10.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 21, 2022
Details:
LL-BMT1 (bimatoprost), a drug-eluting contact lens to treat glaucoma, and is preceded by the successful completion of the Company’s SIGHT-1 study that validated the MediPrint™ process and contact lenses for treating human subjects.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: LL-BMT1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
Details:
NCX 470 is a novel, nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent IOP-lowering effects of NO and prostaglandin analogs (PGAs). NCX 470 incorporates Nicox’s proprietary NO-donating research platform and bimatoprost in a single molecule.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: NCX 470
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 07, 2022
Details:
NCX 470 is a novel, nitric oxide (NO)-donating bimatoprost eye drop that leverages the potent IOP-lowering effects of NO and prostaglandin analogs (PGAs).
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: NCX 470
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2022
Details:
The funds raised in this Series A round are targeted primarily to support the upcoming Phase 2b clinical study along with the end of Phase 2 meeting with the FDA for its lead glaucoma asset, LL-BMT1 (bimatoprost) in patients with open angled glaucoma or ocular hypertension.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: LL-BMT1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 15, 2022
Details:
Under the agreement, Sandoz gained access to both Vistitan and Tacrolimus IR. Vistitan (bimatoprost) is a prostaglandin for IOP lowering in patients with open-angle glaucoma or ocular hypertension.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Vistitan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 11, 2022
Details:
Zimed PF (bimatoprost) a preservative-free, ophthalmic solution, is a prostaglandin approved for the reduction of elevated IOP in patients with open angle glaucoma or ocular hypertension by selectively mimicking the effects of naturally occurring substances, prostamides.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Zimed PF
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2022
Details:
Under this agreement, Medicom has acquired the ownership of the BIMATOPROST 0.3 mg/mL, 3ml dossier which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Zimed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Medicom Healthcare
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 10, 2021
Details:
Under the agreement, Medicom has acquired the ownership of the pharmaceutical dossier of Zimed (bimatoprost), a preservative free eye drop solution, which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: Zimed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Famar
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 09, 2021
Details:
The expanded SAB will provide independent scientific review and guidance to the Company with regards to its R&D activities and product pipeline which includes company’s lead glaucoma asset as well as its products for dry eye, allergy, and other anterior segment conditions.
Lead Product(s): Bimatoprost
Therapeutic Area: Ophthalmology Product Name: LL-BMT1
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
Latisse-Generic (bimatoprost 0.03%) is the first prostaglandin analog that is used for the reduction of elevated intraocular pressure (IOP) in patients with open-angled glaucoma or ocular hypertension.
Lead Product(s): Bimatoprost
Therapeutic Area: Rare Diseases and Disorders Product Name: Latisse-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
